Top > Search of International Patents > PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN

PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN

Foreign code F170009027
File No. (S2015-1633-N0)
Posted date Mar 29, 2017
Country WIPO
International application number 2016JP071899
International publication number WO 2017026276
Date of international filing Jul 26, 2016
Date of international publication Feb 16, 2017
Priority data
  • P2015-156726 (Aug 7, 2015) JP
Title PHARMACEUTICAL COMPOSITION CONTAINING CONJUGATE OF BORON-CONTAINING COMPOUND AND PROTEIN
Abstract In order to establish a means for selectively delivering a large amount of boron to a tumor tissue, provided is a pharmaceutical composition containing a conjugate of a compound represented by formula (I): X-L-Y (in the formula, X represents a group including 10B, L represents a linker, and Y represents a group bound to a lysine residue), and a tumor-accumulative protein having a lysine residue, wherein the molar ratio (mol number of the compound/mol number of the protein) of the compound and protein contained in the composition exceeds 10.
Outline of related art and contending technology BACKGROUND ART
Boron neutron capture therapy (Boron Neutron Capture Therapy; BNCT) is, a low energy thermal neutrons are harmless to the human body with boron was captured by a drug, thermal neutrons10 Bby reaction, in the microenvironment to one cell line α with lithium to generate new cells destroyed cancer cancer therapy.
Low energy thermal neutrons and fast neutrons have a higher energy level is different from, but are harmless to the human body, thermal neutrons10 Breaction, resulting in lithium and helium nuclei (α line), and about 2.4MeV 1 such energy is sufficient to destroy the cells of one energy.
Is an ideal method of treatment of cancer, without a significant obstacle in the normal tissue, and kill cancer cells, the effective BNCT in order to obtain a therapeutic effect on cancer cells selectively boron needs to be delivered.
Immature angiogenesis around the tumor tissue, a characteristic that is easily accumulated fine particles such as liposomes (EPR effect, is Enhanced permeation and retention effect). Based on this characteristic, using liposome delivery system of boron to cancer cells has been developed. For example, the inventors of the present invention, to a second lipid bilayer of the liposome is introduced into the boron compound, can be a very high concentration boron delivery has succeeded in the development of systems (non-patent document 1). In addition, a boron compound is introduced also in the liposome membrane, by introducing a boron compound, the high integration of the boron (non-patent document 2) successful.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • TOKYO INSTITUTE OF TECHNOLOGY
  • Inventor
  • NAKAMURA, Hiroyuki
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close